UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SP-0336: Combination of radionuclides and EBRT from the clinical radiotherapy point of view

Radiotherapy and oncology, 2014, Vol.111, p.S129-S130

Bruland, O.S

2014

Volltextzugriff (PDF)

PD-0414: Biologic targets identified from dynamic 18FDG-PET and implications for image guided radiotherapy

Radiotherapy and oncology, 2013-03, Vol.106, p.S159-S159

2013

Volltextzugriff (PDF)

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

The New England journal of medicine, 2013-07, Vol.369 (3), p.213-223

2013

Volltextzugriff (PDF)

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

European journal of cancer (1990), 2012-03, Vol.48 (5), p.678-686

2012

Volltextzugriff (PDF)

PO-0844 DYNAMIC FDG-PET AND IMPLICATIONS FOR BIOLOGIC IMAGE GUIDED DOSE ESCALATION

Radiotherapy and oncology, 2012-05, Vol.103, p.S329-S330

2012

Volltextzugriff (PDF)

Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial

British journal of dermatology (1951), 2013-08, Vol.169 (2), p.434-440

2013

Volltextzugriff (PDF)

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

The lancet oncology, 2007, Vol.8 (7), p.587-594

2007

Volltextzugriff (PDF)

On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy

European journal of cancer (1990), 1997-10, Vol.33 (11), p.1725-1731

1997

Volltextzugriff (PDF)

7011 A double-blind, randomised dose-response phase II, multicentre study of radium-223 for the palliation of painful bone metastases in castration refractory prostate cancer patients

European journal of cancer supplements, 2009, Vol.7 (2), p.409-409

2009

Volltextzugriff (PDF)

Corrigendum to “Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence” [Prev. Vet. Med. 119 (2015) 48–53]

Preventive veterinary medicine, 2015-06, Vol.120 (2), p.252-252

2015

Volltextzugriff (PDF)

4054 POSTER Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)

European journal of cancer supplements, 2007, Vol.5 (4), p.295-295

2007

Volltextzugriff (PDF)

Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma

Journal of bone oncology, 2013-12, Vol.2 (4), p.174-179

2013

Volltextzugriff (PDF)

68 Bone-seeking radiopharmaceuticals in patients with skeletal metastases. clinical experience using alpha-emitting radium-223

Radiotherapy and oncology, 2006-03, Vol.78, p.S23-S24

2006

Volltextzugriff (PDF)

P102 First-in-human study of AB001, a prostate-specific membrane antigen (PSMA) targeted 212Pb alpha radioligand, in patients with metastatic castration resistant prostate cancer (mCRPC): Phase 0 experience

European urology open science (Online), 2024-11, Vol.69, p.123-123

2024

Volltextzugriff (PDF)

Prediction of long-term survival in metastatic gastrointestinal stromal tumour: analysis of a large, single-institution patient cohort

Annals of oncology, 2016-10, Vol.27, p.vi490-vi490

2016

Volltextzugriff (PDF)

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Prostate cancer and prostatic diseases, 2009-09, Vol.12 (3), p.269-276

2009

Volltextzugriff (PDF)

Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides

Nuclear medicine and biology, 2004-05, Vol.31 (4), p.441-449

2004

Volltextzugriff (PDF)

543 Tolerability of a novel bone-seeking radionuclide — the alpha emitter radium-223 — in patients with skeletal metastases from breast and prostate cancer

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S164-S165

2003

Volltextzugriff (PDF)

Chapter 66 - Targeted radionuclide therapy in bone cancer

Bone Cancer, 2022, p.977-986

Third Edition, 2022

Volltextzugriff (PDF)

Targeted radionuclide therapy in bone cancer

Bone Cancer, 2022, p.977-986

Third Edition, 2022

Volltextzugriff (PDF)

Immunoscintigraphy of bone sarcomas--results in 5 patients

European journal of cancer (1990), 1994, Vol.30A (10), p.1484-1489

1994

Volltextzugriff (PDF)

212Bi-DOTMP: An alpha particle emitting bone-seeking agent for targeted radiotherapy

Nuclear medicine and biology, 1997-04, Vol.24 (3), p.231-237

1997

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)
Buchkapitel
(2)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

SP-0336: Combination of radionuclides and EBRT from the clinical radiotherapy point of view

PD-0414: Biologic targets identified from dynamic 18FDG-PET and implications for image guided radiotherapy

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

PO-0844 DYNAMIC FDG-PET AND IMPLICATIONS FOR BIOLOGIC IMAGE GUIDED DOSE ESCALATION

Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy

7011 A double-blind, randomised dose-response phase II, multicentre study of radium-223 for the palliation of painful bone metastases in castration refractory prostate cancer patients

Corrigendum to “Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence” [Prev. Vet. Med. 119 (2015) 48–53]

4054 POSTER Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)

Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma

68 Bone-seeking radiopharmaceuticals in patients with skeletal metastases. clinical experience using alpha-emitting radium-223

P102 First-in-human study of AB001, a prostate-specific membrane antigen (PSMA) targeted 212Pb alpha radioligand, in patients with metastatic castration resistant prostate cancer (mCRPC): Phase 0 experience

Prediction of long-term survival in metastatic gastrointestinal stromal tumour: analysis of a large, single-institution patient cohort

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides

543 Tolerability of a novel bone-seeking radionuclide — the alpha emitter radium-223 — in patients with skeletal metastases from breast and prostate cancer

Chapter 66 - Targeted radionuclide therapy in bone cancer

Targeted radionuclide therapy in bone cancer

Immunoscintigraphy of bone sarcomas--results in 5 patients

212Bi-DOTMP: An alpha particle emitting bone-seeking agent for targeted radiotherapy

Suchergebnisse filtern